Viropro Initiates Interim Debt Financing of Up to $500,000
PR Newswire - Mon Aug 25, 1:51PM CDT
Viropro, Inc. today announced that it has entered into a definitive agreement with Spring Hill Bioventures outlining the terms through which the company will raise up to $500,000 in convertible debt. Simultaneously, Spring Hill has closed on an initial commitment of $200,000.
Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
PR Newswire Europe - Mon Feb 25, 9:03AM CST
Viropro, Inc. and Oncobiologics, Inc. announced today the signing of a biosimilar collaboration agreement. Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries (excluding China). Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. The alliance will seek regional partners to drive commercialization.